Five-year longitudinal assessment (2008 to 2012) of E-101 solution activity against clinical target and antimicrobial-resistant pathogens

Gerald Denys, Chris M. Pillar, Daniel F. Sahm, Peter O'Hanley, Jackson T. Stephens

Research output: Contribution to journalArticle

Abstract

This study summarizes the topical E-101 solution susceptibility testing results for 760 Gram-positive and Gram-negative target pathogens collected from 75 U.S. sites between 2008 and 2012 and 103 ESKAPE pathogens. E-101 solution maintained potent activity against all bacterial species studied for each year tested, with MICs ranging from<0.008 to 0.25 μg porcine myeloperoxidase (pMPO)/ml. These results confirm that E-101 solution retains its potent broad-spectrum activity against U.S. clinical isolates and organisms with challenging resistance phenotypes.

Original languageEnglish (US)
Pages (from-to)4911-4914
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number8
DOIs
StatePublished - Jan 1 2014

Fingerprint

Peroxidase
Swine
Phenotype

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Five-year longitudinal assessment (2008 to 2012) of E-101 solution activity against clinical target and antimicrobial-resistant pathogens. / Denys, Gerald; Pillar, Chris M.; Sahm, Daniel F.; O'Hanley, Peter; Stephens, Jackson T.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 8, 01.01.2014, p. 4911-4914.

Research output: Contribution to journalArticle

Denys, Gerald ; Pillar, Chris M. ; Sahm, Daniel F. ; O'Hanley, Peter ; Stephens, Jackson T. / Five-year longitudinal assessment (2008 to 2012) of E-101 solution activity against clinical target and antimicrobial-resistant pathogens. In: Antimicrobial Agents and Chemotherapy. 2014 ; Vol. 58, No. 8. pp. 4911-4914.
@article{c6f8b30f934d4b848c6c90c5e7d3f5ad,
title = "Five-year longitudinal assessment (2008 to 2012) of E-101 solution activity against clinical target and antimicrobial-resistant pathogens",
abstract = "This study summarizes the topical E-101 solution susceptibility testing results for 760 Gram-positive and Gram-negative target pathogens collected from 75 U.S. sites between 2008 and 2012 and 103 ESKAPE pathogens. E-101 solution maintained potent activity against all bacterial species studied for each year tested, with MICs ranging from<0.008 to 0.25 μg porcine myeloperoxidase (pMPO)/ml. These results confirm that E-101 solution retains its potent broad-spectrum activity against U.S. clinical isolates and organisms with challenging resistance phenotypes.",
author = "Gerald Denys and Pillar, {Chris M.} and Sahm, {Daniel F.} and Peter O'Hanley and Stephens, {Jackson T.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1128/AAC.03020-14",
language = "English (US)",
volume = "58",
pages = "4911--4914",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Five-year longitudinal assessment (2008 to 2012) of E-101 solution activity against clinical target and antimicrobial-resistant pathogens

AU - Denys, Gerald

AU - Pillar, Chris M.

AU - Sahm, Daniel F.

AU - O'Hanley, Peter

AU - Stephens, Jackson T.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - This study summarizes the topical E-101 solution susceptibility testing results for 760 Gram-positive and Gram-negative target pathogens collected from 75 U.S. sites between 2008 and 2012 and 103 ESKAPE pathogens. E-101 solution maintained potent activity against all bacterial species studied for each year tested, with MICs ranging from<0.008 to 0.25 μg porcine myeloperoxidase (pMPO)/ml. These results confirm that E-101 solution retains its potent broad-spectrum activity against U.S. clinical isolates and organisms with challenging resistance phenotypes.

AB - This study summarizes the topical E-101 solution susceptibility testing results for 760 Gram-positive and Gram-negative target pathogens collected from 75 U.S. sites between 2008 and 2012 and 103 ESKAPE pathogens. E-101 solution maintained potent activity against all bacterial species studied for each year tested, with MICs ranging from<0.008 to 0.25 μg porcine myeloperoxidase (pMPO)/ml. These results confirm that E-101 solution retains its potent broad-spectrum activity against U.S. clinical isolates and organisms with challenging resistance phenotypes.

UR - http://www.scopus.com/inward/record.url?scp=84905368231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905368231&partnerID=8YFLogxK

U2 - 10.1128/AAC.03020-14

DO - 10.1128/AAC.03020-14

M3 - Article

VL - 58

SP - 4911

EP - 4914

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -